|
1
|
Gubbels JAA, Claussen N, Kapur AK, Connor
JP and Patankar MS: The detection, treatment, and biology of
epithelial ovarian cancer. J Ovarian Res. 3:8–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pautier P, Joly F, Kerbrat P, Bougnoux P,
Fumoleau P, Petit T, Rixe O, Ringeisen F, Tisseron Carrasco A and
Lhomme C: Phase II study of gefitinib in combination with
paclitaxel (P) and carboplatin (C) as second-line therapy for
ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol
Oncol. 116:157–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pectasides D, Pectasides E, Papaxoinis G,
Psyrri A, Pliarchopoulou K, Koumarianou A, Macheras A, Athanasas G,
Xiros N and Economopoulos T: Carboplatin/gemcitabine alternating
with carboplatin/pegylated liposomal doxorubicin and
carboplatin/cyclophosphamide in platinum-refractory/resistant
paclitaxel-pretreated ovarian carcinoma. Gynecol Oncol. 118:52–57.
2010. View Article : Google Scholar
|
|
4
|
Ledermann JA and Raja FA: Targeted trials
in ovarian cancer. Gynecol Oncol. 119:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cuzick J, Otto F, Baron JA, Brown PH, Burn
J, Greenwald P, Jankowski J, La Vecchia C and Meyskens F: Aspirin
and non-steroidal anti-inflammatory drugs for cancer prevention: an
international consensus statement. Lancet Oncol. 10:501–507. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Akhmedkhanov A, Toniolo P,
Zeleniuch-Jacquotte A, Kato I, Koenig KL and Shore RE: Aspirin and
epithelial ovarian cancer. Prev Med. 33:682–687. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sporn MB and Hong WK: Concomitant DFMO and
sulindac chemoprevention of colorectal adenomas: a major clinical
advance. Nat Clin Pract Oncol. 5:628–629. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Verheul HMW, Panigrahy D, Yuan J and
D’Amato RJ: Combination oral antiangiogenic therapy with
thalidomide and sulindac inhibits tumour growth in rabbits. Br J
Cancer. 79:114–118. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Uddin S, Ahmed M, Hussain A, Assad L,
Al-Dayel F, Bavi P, Al-Kuraya KS and Munkarah A: Cyclooxygenase-2
inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian
cancer. Int J Cancer. 126:382–394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodriguez-Burford C, Barnes MN,
Oelschlager DK, Myers RB, Talley LI, Partridge EE and Grizzle WE:
Effects of non-steroidal anti-inflammatory agents (NSAIDs) on
ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as
chemopreventive agents. Clin Cancer Res. 8:202–209. 2002.
|
|
11
|
Gupta RA, Tejada LV, Tong BJ, Das SK,
Morrow JD, Dey SK and DuBois RN: Cyclooxygenase-1 is overexpressed
and promotes angiogenic factor production in ovarian cancer. Cancer
Res. 63:906–911. 2003.PubMed/NCBI
|
|
12
|
Munkarah A and Ali-Fehmi R: COX-2: a
protein with an active role in gynecological cancers. Curr Opin
Obstet Gynecol. 17:49–53. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Andrews P, Zhao X, Allen J, Li F and Chang
M: A comparison of the effectiveness of selected non-steroidal
anti-inflammatory drugs and their derivatives against cancer cells
in vitro. Cancer Chemother Pharmacol. 61:203–214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yip-Schneider MT, Wu H, Ralstin M,
Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H,
Sweeney CJ and Schmidt CM: Suppression of pancreatic tumor growth
by combination chemotherapy with sulindac and LC-1 is associated
with cyclin D1 inhibition in vivo. Mol Cancer Ther. 6:1736–1744.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kunte DP, Wali RK, Koetsier JL and Roy HK:
Antiproliferative effect of sulindac in colonic neoplasia
prevention: role of COOH-terminal Src kinase. Mol Cancer Ther.
7:1797–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marotta A, Parhar K, Hundal R, Duronio V
and Salh B: Differential targeting of protein kinase B in cell
death induced by sulindac and its metabolite sulindac sulfide. Int
J Oncol. 28:1471–1479. 2006.PubMed/NCBI
|
|
17
|
Karl T, Seibert N, Stohr M, Osswald H,
Rosl F and Finzer P: Sulindac induces specific degradation of the
HPV oncoprotein E7 and causes growth arrest and apoptosis in
cervical carcinoma cells. Cancer Lett. 245:103–111. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song Z, Tong C, Liang J, Dockendorff A,
Huang C, Augenlicht LH and Yang W: JNK1 is required for
sulindac-mediated inhibition of cell proliferation and induction of
apoptosis in vitro and in vivo. Eur J Pharmacol. 560:95–100. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JS, Baek SJ, Sali T and Eling TE: The
conventional non-steroidal anti-inflammatory drug sulindac sulfide
arrests ovarian cancer cell growth via the expression of
NAG-1/MIC-1/GDF-15. Mol Cancer Ther. 4:487–493. 2005.PubMed/NCBI
|
|
20
|
Nikitakis NG, Hebert C, Lopes MA, Reynolds
MA and Sauk JJ: PPARγ-mediated antineoplastic effect of NSAID
sulindac on human oral squamous carcinoma cells. Int J Cancer.
98:817–823. 2002.
|
|
21
|
Park JH, Kim EJ, Jang HY, Shim H, Lee KK,
Jo HJ, Kim HJ, Yang SH, Jeong ET and Kim HR: Combination treatment
with arsenic trioxide and sulindac enhances apoptotic cell death in
lung cancer cells via activation of oxidative stress and
mitogen-activated protein kinases. Oncol Rep. 20:379–384.
2008.PubMed/NCBI
|
|
22
|
Flis S and Spławiński J: Inhibitory
effects of 5-fluorouracil and oxaliplatin on human colorectal
cancer cell survival are synergistically enhanced by sulindac
sulfide. Anticancer Res. 29:435–442. 2009.PubMed/NCBI
|
|
23
|
Barnes AP, Miller BE and Kucera GL:
Cyclooxygenase inhibition and hyperthermia for the potentiation of
the cytotoxic response in ovarian cancer cells. Gynecol Oncol.
104:443–450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Govindan R, Wang X, Baggstrom MQ,
Burdette-Radoux S, Hodgson L, Vokes EE and Green MR; Cancer and
Leukemia Group B. A phase II study of carboplatin, etoposide, and
exisulind in patients with extensive small cell lung cancer: CALGB
3014. J Thorac Oncol. 4:220–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sinibaldi VJ, Elza-Brown K, Schmidt J,
Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker
SD and Zahurak M: Phase II evaluation of docetaxel plus exisulind
in patients with androgen independent prostate carcinoma. Am J Clin
Oncol. 29:395–398. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oh DH, Bang JS, Choi HM, Yang HI, Yoo MC
and Kim KS: Fetal bovine serum requirement for pyrrolidine
dithiocarbamate-induced apoptotic cell death of MCF-7 breast tumor
cells. Eur J Pharmacol. 649:135–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen D, Peng F, Cui QC, Danie KG, Orlu S,
Liu J and Dou QP: Inhibition of prostate cancer cellular proteasome
activity by a pyrrolidine dithiocarbamate-copper complex is
associated with suppression of proliferation and induction of
apoptosis. Front Biosc. 10:2932–2939. 2005. View Article : Google Scholar
|
|
28
|
Chinery R, Brockman JA, Peeler MO, Shyr Y,
Beauchamp RD and Coffey RJ: Antioxidants enhance the cytotoxicity
of chemotherapeutic agents in colorectal cancer: a p53-independent
induction of p21WAF1/CIP1 via C/EBPβ. Nat Med.
3:1233–1241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Morais C, Gobe G, Johnson DW and Healy H:
Inhibition of nuclear factor kappa B transcription activity drives
a synergistic effect of pyrrolidine dithiocarbamate and cisplatin
for treatment of renal cell carcinoma. Apoptosis. 14:412–425. 2010.
View Article : Google Scholar
|
|
30
|
Liu GH, Wang SR, Wang B and Kong BH:
Inhibition of nuclear factor-κB by an antioxidant enhances
paclitaxel sensitivity in ovarian carcinoma cell line. Int J
Gynecol Cancer. 16:1777–1782. 2006.
|
|
31
|
Gu JW, Young E, Busby B, Covington J, Tan
W and Johnson JW: Oral administration of pyrrolidine
dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis
and growth of breast cancer in female mice. Cancer Biol Ther.
8:514–521. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jakubowska-Mucka A, Sienko J, Switaj T,
Golab J and Lasek W: Antitumor effects of sulindac in ovarian
cancer cell cultures. Ginekol Pol. 82:195–199. 2011.(In
Polish).
|
|
33
|
Chou TC and Talalay P: Quantitive analysis
of dose-effect relationships: the combined effects of multiple
drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seo AM, Hong SW, Shin JS, Park IC, Hong
NJ, Kim DJ, Lee WK, Lee WJ, Jin DH and Lee MS: Sulindac induces
apoptotic cell death in susceptible human breast cancer cells
through, at least in part, inhibition of IKKβ. Apoptosis.
14:913–922. 2009.PubMed/NCBI
|
|
35
|
Yamamoto Y, Yin MJ, Lin KM and Gaynor RB:
Sulindac inhibition activation of the NF-κB pathway. J Biol Chem.
274:27307–27314. 1999.
|
|
36
|
Nakanishi C and Toi M: Nuclear factor κB
inhibitors as sensitizers to anticancer drugs. Nature Rev Cancer.
5:297–309. 2005.
|
|
37
|
Nai YJ, Jiang ZW, Wang ZM, Li N and Li JS:
Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC)
in colon 26 tumor-bearing mice. JPEN J Parenter Enteral Nutr.
31:18–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
O’Connor R, O’Leary M, Ballot J, Collins
CD, Kinsella P, Mager DE, Arnold RD, O’Driscoll L, Larkin A,
Kennedy S, Fennelly D, Clynes M and Crown J: A phase I clinical and
pharmacokinetic study of the multi-drug resistance protein-1
(MRP-1) inhibitor sulindac, in combination with epirubicin in
patients with advanced cancer. Cancer Chemother Pharmacol.
59:79–87. 2007.PubMed/NCBI
|
|
39
|
Moos PJ, Muskardin DT and Fitzpatrick FA:
Effect of taxol and taxotere on gene expression in macrophages:
induction of the prostaglandin H synthase-2 isoenzyme. J Immunol.
162:467–473. 1999.PubMed/NCBI
|
|
40
|
Morais C, Gobe G, Johnson DW and Healy H:
Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear
factor kappa B inhibitor. Angiogenesis. 12:365–379. 2009.
View Article : Google Scholar : PubMed/NCBI
|
